Abomics strengthens its leadership team to support continued growth in precision medicine. New commercial and business development expertise reinforces the company’s ability to expand strategic partnerships and deliver clinically integrated pharmacogenetic solutions that advance personalized healthcare in real-world settings.
Abomics is pleased to share updates to its leadership and team structure as the company continues to grow and strengthen its position in the field of precision medicine.
Henriikka Halinen has been appointed Chief Commercial Officer at Abomics. Henriikka brings more than 20 years of experience in health technology, with a strong background in strategic business development, commercial leadership, and international market expansion. She joined Abomics in April from Philips, and her proven track record in driving growth and fostering innovation will be instrumental in advancing Abomics’ mission to deliver personalized healthcare solutions. Her leadership will play a key role in guiding the company’s continued evolution in the dynamic field of precision medicine.
Phd, Justyna Ulanska-Poutanen has joined Abomics as Business Development Manager. Justyna came on board in early April from Blueprint Genetics, where she most recently served as a Product Manager. She previously held global sales roles focused on rare disease diagnostics. With a strong foundation in molecular medicine and extensive experience in international sales and business development, Justyna brings a unique blend of scientific and commercial expertise. Her global perspective will support Abomics in building strategic partnerships and expanding its international presence in personalized healthcare.
Sami Miettinen, CEO of Abomics, and Dr. Jari Forsström, Chief Medical Officer and Founder, commented:
“As Abomics continues to grow, we consistently assess the capabilities needed to best serve our customers and partners. These new appointments enhance our team’s strength and align with the momentum we’re building for future growth.”
Abomics collaborates with clinical laboratories, clinical research organizations, electronic health record (EHR) providers, genetics companies, and biobanks to deliver pharmacogenetic interpretation services and personalized pharmacogenetic reports. These tools help physicians select the most appropriate medication and dosage based on a patient’s genetic profile.
Abomics also develops medical and pharmaceutical databases that support clinicians in making informed prescribing decisions. In early 2025, Abomics completed its merger with Multirec, a company with over 20 years of experience in providing drug databases and clinical decision support for electronic health records. Multirec’s strong reputation and long-standing partnerships with leading EHR vendors enhance Abomics’ ability to integrate pharmacogenetics into routine clinical workflows in a user-friendly and effective way.
Abomics has appointed a new Lead Bioinformatician to deepen its expertise in genomics and pharmacogenetics. The role strengthens scientific capabilities behind clinically actionable solutions and supports the practical implementation of precision medicine in healthcare settings.
Abomics has renewed its ISO 13485:2016 certification, confirming that its pharmacogenetic reporting and clinical decision support solutions meet internationally recognized quality standards. The certification reinforces consistent, risk-based processes that support safe and reliable implementation.
MD Nora Nikander joins Abomics’ Medical Advisory team, bringing clinical experience from university hospital care and a strong focus on pharmacogenetics. Her expertise supports the development of practical, clinically relevant tools that enable safer, individualized prescribing in everyday healthcare.